CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Passage Bio, Inc. - PASG CFD

    0.68
    13.33%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Passage Bio Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.6
    Open* 0.63
    1-Year Change* -48.78%
    Day's Range* 0.6 - 0.68
    52 wk Range 0.58-1.92
    Average Volume (10 days) 351.79K
    Average Volume (3 months) 4.34M
    Market Cap 33.99M
    P/E Ratio -100.00K
    Shares Outstanding 54.82M
    Revenue N/A
    EPS -2.06
    Dividend (Yield %) N/A
    Beta 0.97
    Next Earnings Date Mar 4, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 27, 2023 0.60 0.02 3.45% 0.58 0.62 0.57
    Nov 24, 2023 0.59 0.01 1.72% 0.58 0.61 0.58
    Nov 22, 2023 0.58 0.00 0.00% 0.58 0.60 0.57
    Nov 21, 2023 0.60 -0.02 -3.23% 0.62 0.62 0.58
    Nov 20, 2023 0.59 0.00 0.00% 0.59 0.60 0.58
    Nov 17, 2023 0.57 -0.03 -5.00% 0.60 0.61 0.57
    Nov 16, 2023 0.58 -0.02 -3.33% 0.60 0.60 0.57
    Nov 15, 2023 0.60 -0.04 -6.25% 0.64 0.65 0.59
    Nov 14, 2023 0.63 0.05 8.62% 0.58 0.63 0.57
    Nov 13, 2023 0.57 -0.01 -1.72% 0.58 0.60 0.56
    Nov 10, 2023 0.57 -0.10 -14.93% 0.67 0.67 0.57
    Nov 9, 2023 0.63 -0.03 -4.55% 0.66 0.68 0.62
    Nov 8, 2023 0.66 -0.02 -2.94% 0.68 0.71 0.65
    Nov 7, 2023 0.67 0.00 0.00% 0.67 0.69 0.65
    Nov 6, 2023 0.65 -0.01 -1.52% 0.66 0.68 0.63
    Nov 3, 2023 0.64 -0.02 -3.03% 0.66 0.68 0.64
    Nov 2, 2023 0.65 0.00 0.00% 0.65 0.68 0.63
    Nov 1, 2023 0.63 0.03 5.00% 0.60 0.63 0.60
    Oct 31, 2023 0.62 -0.02 -3.13% 0.64 0.64 0.61
    Oct 30, 2023 0.63 -0.02 -3.08% 0.65 0.65 0.62

    Passage Bio, Inc. Events

    Time (UTC) Country Event
    Monday, March 4, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Passage Bio Inc Earnings Release
    Q4 2023 Passage Bio Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 138.394 185.729 112.902 37.189 13.466
    Selling/General/Admin. Expenses, Total 49.341 60.056 30.114 6.951 0.928
    Research & Development 89.053 125.673 82.788 30.238 12.538
    Operating Income -138.394 -185.729 -112.902 -37.189 -13.466
    Interest Income (Expense), Net Non-Operating 2.269 0.343 0.67 0.696 0
    Other, Net -9.141 0.696
    Net Income Before Taxes -136.125 -185.386 -112.232 -45.634 -12.77
    Net Income After Taxes -136.125 -185.386 -112.232 -45.634 -12.77
    Net Income Before Extra. Items -136.125 -185.386 -112.232 -45.634 -12.77
    Net Income -136.125 -185.386 -112.232 -45.634 -12.77
    Income Available to Common Excl. Extra. Items -136.125 -185.386 -112.232 -45.634 -12.77
    Income Available to Common Incl. Extra. Items -136.125 -185.386 -112.232 -45.634 -12.77
    Diluted Net Income -136.125 -185.386 -112.232 -45.634 -12.77
    Diluted Weighted Average Shares 54.429 53.344 38.616 39.3983 39.3983
    Diluted EPS Excluding Extraordinary Items -2.50096 -3.4753 -2.90636 -1.15827 -0.32413
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.50096 -3.4753 -2.90636 -1.15827 -0.32413
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 25.388 35.883 28.244 27.526 39.812
    Selling/General/Admin. Expenses, Total 8.064 19.047 10.587 10.664 12.991
    Research & Development 17.324 16.836 17.657 16.862 26.821
    Operating Income -25.388 -35.883 -28.244 -27.526 -39.812
    Interest Income (Expense), Net Non-Operating 1.5 1.1 1.173 0.825 0.27
    Net Income Before Taxes -23.856 -34.338 -27.071 -26.701 -39.542
    Net Income After Taxes -23.856 -34.338 -27.071 -26.701 -39.542
    Net Income Before Extra. Items -23.856 -34.338 -27.071 -26.701 -39.542
    Net Income -23.856 -34.338 -27.071 -26.701 -39.542
    Income Available to Common Excl. Extra. Items -23.856 -34.338 -27.071 -26.701 -39.542
    Income Available to Common Incl. Extra. Items -23.856 -34.338 -27.071 -26.701 -39.542
    Diluted Net Income -23.856 -34.338 -27.071 -26.701 -39.542
    Diluted Weighted Average Shares 54.6838 54.6188 54.5779 54.4739 54.3863
    Diluted EPS Excluding Extraordinary Items -0.43625 -0.62868 -0.49601 -0.49016 -0.72706
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.43625 -0.62868 -0.49601 -0.49016 -0.72706
    Other, Net 0.032 0.445
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 197.044 325.066 317.183 165.775 33.399
    Cash and Short Term Investments 189.61 315.773 304.817 158.874 24.861
    Cash & Equivalents 34.601 128.965 135.002 158.874 24.861
    Prepaid Expenses 7.434 9.293 12.366 6.901 8.538
    Total Assets 243.549 355.076 328.007 178.613 33.461
    Property/Plant/Equipment, Total - Net 42.238 23.806 2.795 1.087 0.028
    Property/Plant/Equipment, Total - Gross 47.391 26.283 1.221 0.028
    Accumulated Depreciation, Total -5.153 -2.477 -0.134 0
    Other Long Term Assets, Total 4.267 6.204 8.029 11.751 0.034
    Total Current Liabilities 18.351 29.498 21.175 3.681 0.307
    Accounts Payable 4.065 9.448 5.265 0.629 0.212
    Accrued Expenses 14.201 19.389 15.369 3.006 0.088
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.085 0.661 0.541 0.046 0.007
    Total Liabilities 42.183 36.419 23.293 4.261 2.516
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 23.832 6.921 2.118 0.58 2.209
    Total Equity 201.366 318.657 304.714 174.352 30.945
    Redeemable Preferred Stock 232.147 43.118
    Common Stock 0.005 0.005 0.004 0.002 0.002
    Additional Paid-In Capital 694.733 675.346 475.617 2.409 0.855
    Retained Earnings (Accumulated Deficit) -492.406 -356.281 -170.895 -58.664 -13.03
    Total Liabilities & Shareholders’ Equity 243.549 355.076 328.007 178.613 33.461
    Total Common Shares Outstanding 54.6147 54.245 45.6148 39.3983 39.3983
    Preferred Stock - Non Redeemable, Net -1.542
    Short Term Investments 155.009 186.808 169.815
    Other Equity, Total -0.966 -0.413 -0.012
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 135.711 153.625 171.621 197.044 222.524
    Cash and Short Term Investments 132.78 151.48 167.774 189.61 213.758
    Cash & Equivalents 33.579 30.291 33.372 34.601 62.568
    Short Term Investments 99.201 121.189 134.402 155.009 151.19
    Prepaid Expenses 2.931 2.145 3.847 7.434 8.766
    Total Assets 169.256 193.696 213.243 243.549 270.052
    Property/Plant/Equipment, Total - Net 33.112 39.638 41.189 42.238 42.808
    Other Long Term Assets, Total 0.433 0.433 0.433 4.267 4.72
    Total Current Liabilities 19.811 19.87 17.243 18.351 21.619
    Accounts Payable 2.749 3.383 3.033 4.065 4.506
    Accrued Expenses 13.062 11.487 10.181 14.201 16.534
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 4 5 4.029 0.085 0.579
    Total Liabilities 42.98 43.282 42.892 42.183 45.656
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 23.169 23.412 25.649 23.832 24.037
    Total Equity 126.276 150.414 170.351 201.366 224.396
    Common Stock 0.005 0.005 0.005 0.005 0.005
    Additional Paid-In Capital 704.173 701.349 697.517 694.733 691.194
    Retained Earnings (Accumulated Deficit) -577.71 -550.6 -526.744 -492.406 -465.335
    Other Equity, Total -0.192 -0.34 -0.427 -0.966 -1.468
    Total Liabilities & Shareholders’ Equity 169.256 193.696 213.243 243.549 270.052
    Total Common Shares Outstanding 54.813 54.7457 54.6267 54.6147 54.5466
    Property/Plant/Equipment, Total - Gross 39.54 46.612 47.32 47.391 47.016
    Accumulated Depreciation, Total -6.428 -6.974 -6.131 -5.153 -4.208
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -136.125 -185.386 -112.232 -45.634 -12.77
    Cash From Operating Activities -118.21 -126.879 -80.52 -39.896 -18.567
    Cash From Operating Activities 3.679 1.543 0.8 0.134 0
    Non-Cash Items 22.727 45.544 16.472 11.547 2.727
    Changes in Working Capital -8.491 11.42 14.44 -5.943 -8.524
    Cash From Investing Activities 25.199 -45.814 -172.106 -1.693 -2.543
    Capital Expenditures -5.274 -25.642 -1.646 -1.693 -2.543
    Cash From Financing Activities -1.353 166.656 228.754 175.602 45.971
    Financing Cash Flow Items -1.786 -0.338 -0.763 0
    Issuance (Retirement) of Stock, Net 0.433 166.994 228.754 176.365 45.971
    Net Change in Cash -94.364 -6.037 -23.872 134.013 24.861
    Other Investing Cash Flow Items, Total 30.473 -20.172 -170.46
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -34.338 -136.125 -109.054 -82.353 -42.811
    Cash From Operating Activities -22.446 -118.21 -94.189 -70.794 -44.711
    Cash From Operating Activities 0.978 3.679 2.733 1.804 0.883
    Non-Cash Items 2.686 22.727 19.683 15.266 8.712
    Changes in Working Capital 8.228 -8.491 -7.551 -5.511 -11.495
    Cash From Investing Activities 21.217 25.199 28.557 33.315 17.311
    Capital Expenditures -0.026 -5.274 -4.8 -3.056 -2.225
    Other Investing Cash Flow Items, Total 21.243 30.473 33.357 36.371 19.536
    Cash From Financing Activities 0 -1.353 -0.765 -0.357 0.049
    Financing Cash Flow Items -1.786 -1.136 -0.649
    Issuance (Retirement) of Stock, Net 0 0.433 0.371 0.292 0.049
    Net Change in Cash -1.229 -94.364 -66.397 -37.836 -27.351
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 18.4717 10124576 1192577 2023-06-30 LOW
    Versant Ventures Venture Capital 9.0488 4959769 0 2023-06-30 LOW
    New Leaf Venture Partners LLC Venture Capital 4.5573 2497922 0 2023-06-30 LOW
    BML Capital Management LLC Investment Advisor 3.7561 2058767 0 2023-09-30 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.6815 2017883 0 2023-06-30 LOW
    Frazier Healthcare Partners Venture Capital 3.3752 1850000 -1906915 2023-06-30 LOW
    Lynx1 Capital Advisors LLC Investment Advisor 2.1297 1167343 -2240255 2023-06-30 MED
    Renaissance Technologies LLC Hedge Fund 1.7863 979095 14195 2023-06-30 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 1.3918 762871 7171 2023-06-30 LOW
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.056 578806 0 2023-06-30 MED
    Two Sigma Investments, LP Hedge Fund 0.9636 528162 -71264 2023-06-30 HIGH
    Acuitas Investments LLC Investment Advisor/Hedge Fund 0.7629 418161 -12 2023-09-30 HIGH
    Bridgeway Capital Management, LLC Investment Advisor 0.7108 389600 0 2023-06-30 MED
    Weiss Multi-Strategy Advisers LLC Hedge Fund 0.6708 367696 0 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.6056 331914 0 2023-06-30 LOW
    Tang Capital Management, LLC Hedge Fund 0.5473 300000 0 2023-06-30 MED
    Bellecapital Partners AG Investment Advisor/Hedge Fund 0.4785 262283 0 2023-02-28 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.4163 228175 -5948 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 0.3785 207463 -90627 2023-06-30 HIGH
    RBF Capital, LLC Hedge Fund 0.2605 142807 32000 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Passage Bio, Inc. Company profile

    About Passage Bio Inc

    Passage Bio, Inc. is a clinical-stage genetic medicines company. It is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (β-gal) for gangliosidosis (GM1). Its second product candidate, PBFT02, utilizes AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN) for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC) for Krabbe disease. It also has four programs in the research stage: PBML04 for metachromatic leukodystrophy (MLD); PBAL05 for amyotrophic lateral sclerosis (ALS); PBCM06 for Charcot-Marie-Tooth Type 2A (CMT2A), and other.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Passage Bio Inc revenues was not reported. Net loss increased 65% to $185.4M. Higher net loss reflects Research and development increase of 34% to $102.2M (expense), General and administrative increase from $21.1M to $42.8M (expense), Stock-based Compensation in R&D increase from $5.5M to $15.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.91 to -$3.48.

    Industry: Bio Therapeutic Drugs

    One Commerce Square
    2005 Market Street, 39Th Floor
    PHILADELPHIA
    PENNSYLVANIA 19103
    US

    Income Statement

    • Annual
    • Quarterly

    News

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023
    Gold bars

    XAU/USD Latest: Gold advances as weaker data weighs on US yields

    Gold moves higher as softer economic data weighs on US yields and the dollar

    13:43, 17 November 2023

    People also watch

    Gold

    2,049.03 Price
    +1.730% 1D Chg, %
    Long position overnight fee -0.0192%
    Short position overnight fee 0.0110%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Oil - Crude

    76.81 Price
    +2.260% 1D Chg, %
    Long position overnight fee -0.0187%
    Short position overnight fee -0.0032%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    US100

    16,033.60 Price
    +0.450% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    38,047.95 Price
    +2.710% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading